Page 3 - Diabetes
No suicidal thoughts link to diabetes, obesity drugs, finds UK regulator
The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of safety data for the class of drugs, known as GLP-1 receptor agonists, more than a year ago
All you need to know about Type 1.5 diabetes, a mix of type 1 and type 2
Also known as latent autoimmune diabetes in adults (LADA), type 1.5 diabetes has features of both type 1 and type 2 diabetes
Red meat linked with increased diabetes risk; Lancet study gives evidence
Consuming red meat is related to a higher risk of type 2 diabetes, according to an analysis of more than 19 lakh adults from 20 countries across world regions, including southeast Asia, providing the "most comprehensive evidence to date." Published in The Lancet Diabetes and Endocrinology journal, the analysis found that a habitual consumption of three types of meat and their daily amounts - 50 grams of processed meat, 100 grams of unprocessed red meat and 100 grams of poultry - was related to 15 per cent, 10 per cent and eight per cent increases in risk of developing type 2 diabetes, respectively. The international team of researchers from the US, UK, Brazil, Mexico, among others, said that intake of meat exceeds recommended levels in many regions of the world and has been correlated with non-communicable diseases, including type 2 diabetes. However, all the existing evidences are largely based on studies from high-income countries, mainly in North America and Europe, they said. F
Fitterfly collab with Google Cloud to launch AI feature for diabetic people
Fitterfly Klik uses AI computer vision paired with the Fitterfly Nutrition Database, comprising over 37,000 Indian foods, to recognize, analyze, and break down food
Antidiabetic drug Semaglutide linked to potential vision loss: Study
Researchers say future study required to assess causality
Every 3rd Indian affected by fatty liver disease: Minister Jitendra Singh
Union Minister of Science and Technology launches the Indo-French Liver and Metabolic Disease Network to find India-specific interventions for metabolic disorders
India to make Ozempic-like drugs for diabetes, obesity under PLI by 2026
GLP-1RA works by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release responses
Olympic athletes turn to diabetes tech in pursuit of winning medals
The Paris Olympics, which start on July 26, are an opportunity to showcase the technology - even though there is as yet no proof it can boost athletic performance
Can diabetes be cured? Chinese doctors claim breakthrough with cell therapy
A 59-year-old man with type 2 diabetes received an innovative cell transplant and has been insulin-free and off medication for 33 months, offering hope to other diabetes patients
Not so sweet anymore: How India's relationship with sugar is turning sour
With rising incomes, education, and health awareness in India, especially in the big cities, droves of people are saying no to sugar
Asking for insulin daily: Kejriwal writes to Tihar superintendent
Delhi Chief Minister Arvind Kejriwal on Monday wrote to superintendent of Tihar jail where he is lodged since April 1, claiming he has been asking for insulin every day and that AIIMS doctors never said there was no reason to worry about his diabetic condition. His letter to the superintendent comes a day after the Tihar administration issued a statement stating they had arranged his video conference with senior specialists from AIIMS during which neither "the issue of insulin was raised by Kejriwal, nor was it suggested by the doctors". The chief minister alleged that the Tihar administration issued a "false and misleading" statement under "political pressure". There was no immediate reaction from Tihar jail authorities on Delhi chief minister's allegations. Delhi cabinet minister Atishi shared Kejriwal's letter on her X handle. The chief minister rejected the jail administration's claim that the issue of insulin was never raised by him in his consultations with the doctors. "Th
'Conspiracy to kill Kejriwal': AAP says he's being denied insulin in jail
'ED should be afraid of God for lying so much; AAP to hold protests in Delhi: Party leaders
Biocon partners Biomm SA to commercialise it's diabetes drug in Brazil
Biotechnology firm Biocon on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation. Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market. Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima. "Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides," Biocon CEO and MD Siddharth Mittal said in a statement. This is also in line with the growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products, he added. "We are confident that our collaboration with Biomm will provide patients in Brazil, who are livi
Besides Covid-19, diabetes and renal disease reduce Indian lifespan
Covid-19 was the leading cause of death in India, as per the study. The age-standardised rate of deaths for both males and females was 156.8 per 100,000 population
Preventive online health checkups rise 50% in India: Simpl Checkout Scan
Lifestyle-based checkups including diabetes, vitamin deficiency and hair fall, apart from comprehensive full-body checkups, are the most preferred by Indians
Non-Covid deaths high in people with diabetes, women affected more: Study
Non-Covid-related deaths increased among people having diabetes because of pandemic-related disruptions, new research published in The Lancet Diabetes and Endocrinology journal has found. The global review of studies comparing pre-pandemic and during-pandemic data found that the complication of sight loss in people with diabetes also increased. The negative impacts were most pronounced for women, younger people and racial and ethnic minority groups, it found. The team of researchers, including those from the World Health Organization (WHO), looked at 138 studies - North America (39), Western Europe (39), Asia (17) and others from Eastern Europe, South America, Egypt, Australia and multiple regions - to examine the impacts of pandemic-related disruptions on the vulnerable diabetic population. The research findings pointed to the importance of ensuring that all people with diabetes, especially those from the less advantaged groups, had consistent access to diabetes medication and care
Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch
Drug, marketed under the brand name Lirafit, is priced at approximately Rs 100 for a standard daily dose of 1.2 mg
Glenmark Pharmaceuticals launches antidiabetic drug 'Lirafit' in India
Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W
50% surge in diabetes in individuals under 40 yrs of age, say experts
India is often dubbed as the diabetic capital of the world where nearly 11 per cent of the population is grappling with the disease
